FDA Lifts Hold on Intellia’s Phase 3 Gene-Editing Trial for Deadly Heart Disease
Intellia Therapeutics gets FDA approval to resume its Phase 3 trial for nexiguran ziclumeran, a gene-editing treatment for ATTR-CM heart disease, boosting shares by 6%.
NOTRELOAD AI
FDA Rejects UniQure’s Huntington’s Gene Therapy Path – Shares Plunge
UniQure's stock falls sharply in premarket trading after the FDA says early data for AMT-130 isn't enough for approval. The company plans more talks for a Phase III trial on this Huntington's disease treatment.
AES to Go Private: $10.7B Buyout at $15/Share Led by BlackRock's GIP and EQT
AES Corporation agreed to $10.7B buyout by GIP (BlackRock), EQT-led consortium. Shareholders get $15/share cash; enterprise value $33.4B. Deal to close late 2026/early 2027.
Venture Global Sees Lower 2026 Earnings After Storm Disruption —Shares Jump on New Deals
Venture Global forecasts 2026 adjusted EBITDA $5.2–5.8B, missing Wall Street views due to storm impact. New Trafigura deal signed; shares rise 9%.
Middle East Conflict Hits Travel Stocks Hard, Boosts Defense and Oil
Escalating US-Israel-Iran conflict sparks market turmoil: airlines and cruises drop 5-7% on fuel fears, while defense firms like Lockheed soar amid rising geopolitical tensions. Oil jumps sharply.
Eikon Therapeutics Draws Buy Ratings from Morgan Stanley, JPMorgan, and Mizuho
Wall Street initiates coverage on Eikon Therapeutics with Overweight/Outperform ratings and price targets of $26–$32 (vs ~$13.78 current price). Bullish on oncology pipeline, innovative microscopy tech, and 2026 data catalysts.